Citations

Clear

3942 citation(s) found for "To, Van".

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Kelley, Robin Kate , Furuse, Junji , Toni, Enrico N. De , Vasilyev, Alexander, Heurgué, Alexandra , Mody, Kabir , Thungappa, Satheesh Chiradoni, Negro, Alejandra , Abou‐Alfa, Ghassan K. , Chan, Stephen L. , Kudo, Masatoshi , Lau, George , Furuse, Junji , Sukeepaisarnjaroen, Wattana , Kang, Yoon‐Koo , Dao, Tu Van , Rimassa, Lorenza , Breder, Valeriy Vladimirovich , Tam, Vincent C. , He, Philip , Sangro, Bruno

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 379-379

10.1200/jco.2022.40.4_suppl.379 Get It

379 Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single T Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity in a phase 2 uHCC study (Study 22, NCT02519348), suggesting single exposure to T is sufficient to improve upon D activity. HIMALAYA (NCT03298451) evaluated the efficacy and safety of STRIDE or D vs sorafenib (S) in uHCC. Methods: HIMALAYA is an open-label, multicenter, phase 3 study, in which pts with uHCC and no prior systemic therapy were initially randomized to STRIDE (T 300 mg plus D 1500 mg [one dose] plus D 1500 mg every 4 weeks [Q4W]), D (1500 mg Q4W), S (400 mg twice daily), or T 75 mg Q4W (4 doses) plus D 1500 mg Q4W (T75+D). Recruitment to T75+D ceased after a planned analysis of Study 22 showed T75+D did not meaningfully differ from D. The primary objective was overall survival (OS) for STRIDE vs S. The secondary objective was OS noninferiority (NI) of D to S (NI margin: 1.08). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR; RECIST v.1.1), duration of response (DoR), and safety. Results: In total, 1171 pts were randomized to STRIDE (N=393), D (N=389), or S (N=389). At data cutoff (DCO), the primary objective was met: OS was significantly improved for STRIDE vs S (hazard ratio [HR], 0.78; 96% confidence interval [CI], 0.65–0.92; p=0.0035; Table). D met the objective of OS NI to S (HR, 0.86; 96% CI, 0.73–1.03). ORRs were higher for STRIDE (20.1%) and D (17.0%) than for S (5.1%). No new safety signals were identified. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 25.8% (STRIDE), 12.9% (D), and 36.9% (S) of pts. Grade 3/4 hepatic TRAEs occurred in 5.9% (STRIDE), 5.2% (D), and 4.5% (S) of pts. No TRAE of esophageal varices hemorrhage occurred. Rates of TRAEs leading to discontinuation were 8.2% (STRIDE), 4.1% (D), and 11.0% (S). Conclusions: HIMALAYA was the first large phase 3 trial with a diverse, representative uHCC population and extensive long-term follow-up to assess both mono- and combination immunotherapy. D was noninferior to S with favorable safety. The combination of a single priming dose of T plus D in STRIDE displayed superior efficacy and a favorable benefit-risk profile vs S. STRIDE is a proposed, novel, first-line standard of care systemic therapy for uHCC. Clinical trial information: NCT03298451. [Table: see text]
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
Tine, Brian Andrew Van, Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Pelham, Joshua, Anand, Banmeet S. , Strack, Thomas , Sandri, Andrés Machado, Hubbard, Joleen M. , Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Lerner, Susan A. , Wainberg, Zev A.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 297-297

10.1200/jco.2022.40.4_suppl.297 Get It

297 Background: MT-5111 is a 55 kD engineered toxin body (ETB) targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may demonstrate efficacy in patients (pts) resistant to other HER2-targeting agents, as its mechanism of action induces direct cell kill via enzymatic and permanent ribosome destruction and does not rely on inhibition of kinase signaling or cytoskeletal or DNA damage. Methods: This is a phase 1 study in adult pts with advanced HER2+ solid tumors. The dose-escalation portion (modified 3+3 design) enrolls pts into sequential cohorts followed by expansion cohorts for HER2+ breast cancer (BC), gastric or gastroesophageal junction adenocarcinoma (GEA), and other HER2+ tumors. MT-5111 is dosed weekly IV over 30 min in each 21-day treatment (tx) cycle until disease progression, unacceptable toxicity, death, or withdrawn consent. Results: As of Sep 2021 (contains preliminary data), 24 pts (mean age 64 yrs) were treated, 13 (54%) of whom had gastrointestinal (GI) tumors (6 biliary, 3 GEA, 2 pancreatic, 2 colo/rectal) (Table). Pts with GI tumors had a median of 3 prior systemic tx and 1 prior HER2-targeting tx. No Grade (G) 4/5 tx-emergent adverse events (AEs) occurred. Tx-related AEs occurred in 13 (54%) pts, most commonly fatigue (n=7, 29%). One pt with biliary cancer and concurrent lymphangitic carcinomatosis and H. influenzae infection (4.5 µg/kg) had a possibly related G3 serious AE (SAE) of dyspnea, which resolved 9 days later. Another related SAE occurred in a pt with GEA (6.75 µg/kg) who had a G1 transient troponin increase that resolved during hospitalization, with no clinical symptoms or ECG/ECHO changes; the pt withdrew from study before further dosing. All other related AEs were ≤G2. No other clinically significant changes in cardiac biomarkers (troponin, ECG, LVEF) or cases of capillary leak syndrome occurred. Two pts (3 and 4.5 µg/kg) had reversible G2 infusion-related reactions. Best response to date has been stable disease. AUClast data matched PK simulations based on non-human primate studies. Cmax data at 10 µg/kg indicate that current in-pt exposure was between IC50 values of high and medium HER2-expressing cell lines (approx 10-89 ng/mL). Thus, at least 10 µg/kg may be required to achieve effective exposure. No dose-limiting toxicities have been observed. The 10 µg/kg cohort is now accruing. Following this cohort, an expansion cohort for pts with BC will open. Conclusions: MT-5111 was well tolerated with no clinically significant immuno/cardiotoxicity. Dose escalation is ongoing and is nearing levels expected to be required for efficacious exposure. Clinical trial information: NCT04029922. [Table: see text]
In Reply: Anterior Nucleus of the Thalamus Deep Brain Stimulation With Concomitant Vagus Nerve Stimulation for Drug-Resistant Epilepsy
Parisi, Veronica, Gompel, Jamie J. Van , Van Gompel, Jamie J , Parisi, Veronica

Mayo Clinic

Neurosurgery | January 19, 2022 | Volume: 90 | Issue: 4 | Pages: e103-e103

10.1227/neu.0000000000001827 | PMID 35045060 Get It

Considerations for the Use of Phage Therapy in Clinical Practice
Suh, Gina A. , Lodise, Thomas P. , Tamma, Pranita D. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Barton, Karen D., Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J. , Sund, Zoe, Tyne, Daria Van , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Barton, Karen D. , van Duin, David , Van Tyne, Daria , Patel, Robin , Tamma, Pranita D , Suh, Gina A , Lodise, Thomas P. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J , Sund, Zoe, Group, for the Antibacterial Resistance Leadership

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 18, 2022 | Volume: 66 | Issue: 3 | Pages: No page available

10.1128/aac.02071-21 | PMID 35041506 Get It

Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.
Transpharyngeal Approaches for Management of Oropharyngeal Squamous Cell Carcinoma: Mayo Clinic Institution Experience
Badaoui, Joseph N. , Sauer, Adam , Moore, Eric J. , Lohse, Christine M. , Kasperbauer, Jan L. , Noel, Daniel B., Olsen, Kerry D., Abel, Kathryn M. Van , Sauer, Adam B, Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 18, 2022 | Volume: 167 | Issue: 3 | Pages: 509-516

10.1177/01945998211071000 | PMID 35041566 Get It

ObjectiveInvestigate oncologic and functional outcomes associated with transhyoid and lateral pharyngotomy (transpharyngeal) approaches in the treatment of oropharyngeal squamous cell carcinoma (OPSCC).Study DesignRetrospective review.SettingSingle institution (tertiary care center).MethodsThis is a retrospective case series of patients with OPSCC undergoing transpharyngeal resection from 1990 to 2017 at Mayo Clinic. Oncologic outcomes, postoperative complications, objective swallowing data, and rates of tracheostomy and percutaneous gastrostomy tube dependence were recorded.ResultsOf 83 patients meeting inclusion criteria, 56 (68%) were human papillomavirus positive. Overall survival rates at 5 and 10 years following surgery were 85% and 80%, respectively. Cancer‐specific survival rates at these same time points were 90% and 88%. Following treatment, 35 of 49 patients (71%) had a Functional Oral Intake Scale score ≥5, indicating total oral intake of multiple consistencies; 79 of 82 (96%) were without tracheostomy or laryngectomy; and 71 of 81 (88%) were on a full oral diet.ConclusionTranspharyngeal approaches provide adequate functional and oncologic outcomes in the majority of patients with OPSCC. These results may have important implications for patients who are not candidates for, or are unwilling to undergo, nonoperative therapy or for those without access to radiation therapy.
Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis
Murphy, Neil , Song, Mingyang , Papadimitriou, Nikos , Carreras‐Torres, Robert , Langenberg, Claudia , Martin, Richard M. , Tsilidis, Konstantinos K. , Barroso, Inês , Chen, Ji , Vincent, Emma E. , Cotterchio, Michelle , Gruber, Stephen B. , Pai, Rish K. , Perez‐Cornago, Aurora , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Vodička, Pavel , Wu, Anna H. , Peters, Ulrike , Gunter, Marc J. , Frayling, Timothy M , Bull, Caroline J , Vincent, Emma E , Gruber, Stephen B , Pai, R K , Perez-Cornago, Aurora , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Chan, Andrew T , Gunter, Marc J , Murphy, Neil , Martin, Richard M , Song, Mingyang , Carreras-Torres, Robert , Tsilidis, Konstantinos K , Papadimitriou, Nikos , Vodicka, Pavel , Bull, Caroline J. , Newcomb, Polly A. , Wolk, Alicja , Chan, Andrew T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 14, 2022 | Volume: 114 | Issue: 5 | Pages: 740-752

10.1093/jnci/djac011 | PMID 35048991 Get It

Abstract Background Glycemic traits—such as hyperinsulinemia, hyperglycemia, and type 2 diabetes—have been associated with higher colorectal cancer risk in observational studies; however, causality of these associations is uncertain. We used Mendelian randomization (MR) to estimate the causal effects of fasting insulin, 2-hour glucose, fasting glucose, glycated hemoglobin (HbA1c), and type 2 diabetes with colorectal cancer. Methods Genome-wide association study summary data were used to identify genetic variants associated with circulating levels of fasting insulin (n = 34), 2-hour glucose (n = 13), fasting glucose (n = 70), HbA1c (n = 221), and type 2 diabetes (n = 268). Using 2-sample MR, we examined these variants in relation to colorectal cancer risk (48 214 case patient and 64 159 control patients). Results In inverse-variance models, higher fasting insulin levels increased colorectal cancer risk (odds ratio [OR] per 1-SD = 1.65, 95% confidence interval [CI] = 1.15 to 2.36). We found no evidence of any effect of 2-hour glucose (OR per 1-SD = 1.02, 95% CI = 0.86 to 1.21) or fasting glucose (OR per 1-SD = 1.04, 95% CI = 0.88 to 1.23) concentrations on colorectal cancer risk. Genetic liability to type 2 diabetes (OR per 1-unit increase in log odds = 1.04, 95% CI = 1.01 to 1.07) and higher HbA1c levels (OR per 1-SD = 1.09, 95% CI = 1.00 to 1.19) increased colorectal cancer risk, although these findings may have been biased by pleiotropy. Higher HbA1c concentrations increased rectal cancer risk in men (OR per 1-SD = 1.21, 95% CI = 1.05 to 1.40), but not in women. Conclusions Our results support a causal effect of higher fasting insulin, but not glucose traits or type 2 diabetes, on increased colorectal cancer risk. This suggests that pharmacological or lifestyle interventions that lower circulating insulin levels may be beneficial in preventing colorectal tumorigenesis.
Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis
Perou, Charles M. , Hinoue4, Toshinori, Wheeler, Gregory , Kelly, Benjamin , Garrido-Castro, Ana C. , Cubas, Aguirre De, Rajkovic, Andrei, Karaesmen, Ezgi , Fan, Cheng, Creighton, Chad J. , Leraas, Kristen , Burns, Robyn, Coppens, Sara E. , Wheless, Amy, Rezk, Salma, Garrett, Amy, Foy, Kelly K. , Park, Ben, Krop, Ian E. , Anders, Carey K. , Rimawi, Mothaffar F. , Nanda, Rita , Storniolo, Anna Maria , Chandran, Uma , Davis, Michael J. , Ropelewski, Alexander J. , Liu, Minetta C. , Richardson, Andrea L. , Symmans, W. Fraser , Davidson, Nancy E. , King, Tari A. , Perou, Charles M , Rimawi, Mothaffar , Symmans, W Fraser , García‐Recio, Susana , Hinoue4, Toshinori, Pascual, Tomás , Xia, Youli , McClure, Marni B. , Smith, Markia A. , Fan, Cheng, Bowen, Jay , Parker, Joel S. , Shen, Hui , Gastier‐Foster, Julie M. , Lin, Nancy U. , Isaacs, Claudine , Marcom, Paul Kelly , Couch, Fergus J. , Silverstein, Jonathan C. , Hilsenbeck, Susan Galloway , Norton, Larry , Wolff, Antonio C. , Carey, Lisa A. , Lee, Adrian V. , Balko, Justin M. , Hoadley, Katherine A. , Laird, Peter W. , Mardis, Elaine R.

Mayo Clinic

No container title available | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1221704/v1 Get It

Abstract Patients with metastatic breast cancer (MBC) typically have short survival times and their successful treatment represents one of most challenging aspects of patient care. This poor prognostic behavior is in part due to molecular features including increased tumor cell clonal heterogeneity, multiple drug resistance mechanisms, and alterations of the tumor microenvironment. The AURORA US Metastasis Project was established with the goal to identify molecular features specifically associated with metastasis. We therefore collected and molecularly characterized specimens from 55 metastatic breast cancer (BC) patients representing 51 primary cancers and 102 metastases. The 153 unique tumors were assayed using RNAseq, tumor/germline DNA exomes and low pass whole genome sequencing, and global DNA methylation microarrays. We found intrinsic molecular subtype differences between primary tumors and their matched metastases to be rare in triple negative breast cancer (TNBC)/Basal-like subtype tumors. Conversely, tumor subtype changes were relatively frequent in estrogen receptor positive (ER+) cancers where ~30% of Luminal A cases switched to Luminal B or HER2-enriched (HER2E) subtypes. Clonal evolution studies identified changes in expression subtype coincident with DNA clonality shifts, especially involving HER2 amplification and/or the HER2E expression subtype. We further found evidence for ER-mediated downregulation of genes involved in cell-cell adhesion in metastases. Microenvironment differences varied according to tumor subtype where ER+/Luminal metastases had lower fibroblast and endothelial cell content, while TNBC/Basal-like metastases showed a dramatic decrease in B cells and T cells. In 17% of metastatic tumors, we identified DNA hypermethylation and/or focal DNA deletions near HLA-A that were associated with its’ significantly reduced expression, and with lower immune cell infiltrates. We also identified low immune cell features in brain and liver metastases when compared to other metastatic sites, even within the same patient. These findings have direct implications for the treatment of metastatic breast cancer patients with immune- and HER2-targeting therapies and suggest potential novel therapeutic avenues for the improvement of outcomes for some patients with MBC.
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS
Katz, Jonathan, Cudkowicz, Merit , Genge, Angela , Oskarsson, Björn , Hains, Avis B., Galanter, Joshua , Burgess, Braydon L., Kerchner, Geoffrey A. , Yeh, Felix L. , Ghosh, Arundhati Sengupta, Cheeti, Sravanthi , Brooks, Logan , Honigberg, Lee , Couch, Jessica A. , Rothenberg, Michael E. , Brunstein, Flávia, Sharma, Khema R., Berg, Leonard van den , Glass, Jonathan D. , Glass, Jonathan D , Oskarsson, Björn , Cudkowicz, Merit E , Rothstein, Jeffrey D. , Chen, Chen , Cho, Yong‐Yeon , Brooks, Logan, Berry, James D.

Mayo Clinic

Annals of Clinical and Translational Neurology | January 11, 2022 | Volume: 9 | Issue: 1 | Pages: 50-66

10.1002/acn3.51491 | PMID 35014217 Get It

AbstractObjectiveDual leucine zipper kinase (DLK), which regulates the c‐Jun N‐terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS). This first‐in‐human study investigated safety, tolerability, and pharmacokinetics (PK) of oral GDC‐0134, a small‐molecule DLK inhibitor. Plasma neurofilament light chain (NFL) levels were explored in GDC‐0134‐treated ALS patients and DLK conditional knockout (cKO) mice.MethodsThe study included placebo‐controlled, single and multiple ascending‐dose (SAD; MAD) stages, and an open‐label safety expansion (OLE) with adaptive dosing for up to 48 weeks.ResultsForty‐nine patients were enrolled. GDC‐0134 (up to 1200 mg daily) was well tolerated in the SAD and MAD stages, with no serious adverse events (SAEs). In the OLE, three study drug‐related SAEs occurred: thrombocytopenia, dysesthesia (both Grade 3), and optic ischemic neuropathy (Grade 4); Grade ≤2 sensory neurological AEs led to dose reductions/discontinuations. GDC‐0134 exposure was dose‐proportional (median half‐life = 84 h). Patients showed GDC‐0134 exposure‐dependent plasma NFL elevations; DLK cKO mice also exhibited plasma NFL compared to wild‐type littermates.InterpretationThis trial characterized GDC‐0134 safety and PK, but no adequately tolerated dose was identified. NFL elevations in GDC‐0134‐treated patients and DLK cKO mice raised questions about interpretation of biomarkers affected by both disease and on‐target drug effects. The safety profile of GDC‐0134 was considered unacceptable and led to discontinuation of further drug development for ALS. Further work is necessary to understand relationships between neuroprotective and potentially therapeutic effects of DLK knockout/inhibition and NFL changes in patients with ALS.